Merck KGaA SWOT and PESTLE Analysis
COMPANY PROFILE -Merck KGaA
Business Sector :Pharmaceuticals and Chemicals
Operating Geography :Germany, Europe, Global
About Merck KGaA :
The Merck Group (commonly known as Merck) is one of the oldest multinational chemical and pharmaceutical company globally, founded in 1668 by Friedrich Jacob Merck. Entire business of the group can be broadly divided into three categories: Healthcare, Life Science and Electronics. Headquartered in Darmstadt, Germany, Merck operates in 66 countries with more than 60,348 employees as of 2021. Merck has operations throughout Europe, Africa, Asia, Oceania, and the Americas. It has major research and development centres in Darmstadt, Boston, Tokyo, and Beijing, as well as other R&D units in Taiwan, France, Israel, South Korea, India, and the United Kingdom. Merck announced a collaboration with Agilent Technologies to advance Process Analytical Technologies (PAT) in June 2022. PAT is a critical enabler for real-time release and Bioprocessing 4.0, and is strongly encouraged by global regulatory authorities.
The USP of Merck lies in it being ranked under Top 10 largest pharma companies in the world. Merck’s mission is “to improve health and well-being and help people in low- and middle-income countries and underserved regions to lead better lives.”
Merck KGaA Revenue :
€ 19,687 million – FY ended 31st December 2021 (year-on-year growth of 12.3%)
€ 17,534 million – FY ended 31st December 2020
Ownership / Major shareholders :
Merck family is the majority owner of the company and holds 70.3% of the shares as of 2021.Competitive Analysis of Merck KGaA
1. Global leader in fertility drugs and treatment 2. Continued investments to expand capabilities and production 3. Consistently strong financial performance 4. Risk diversified business portfolio 5. Strong focus on R&D to introduce new product offerings 6. Strong Investment grade rating | 1. Weak player in Latin America, middle east and Africa |
1. Great potential to dominate future automotive and lighting display market 2. Accelerating demand of semiconductor materials 3. Growth in pharmaceutical industry due to Covid-19 4. Leveraging e-commerce and distribution platform 5. Growth due to CRISPR technology | 1. Changes in political landscape of Europe: Brexit and growing protectionism 2. Increasing relevance of emerging markets 3. Negative political and macroeconomic developments |
Complete Report
USD 15.53
- Debit/Credit card
- PayPal
Detailed SWOT Analysis of Merck KGaA
Strength
1. Global leader in fertility drugs and treatment: The fertility franchise of Merck, which dominates the global market for fertility medications and treatments, is a significant growth engine for its Biopharma division. The leading therapeutic within its fertility portfolio, GONAL-f®2, has assisted in the birth of more than 4 million children to date. With the introduction of its Gonal-f® (follitropin alfa) 150 IU pen, Merck provided patients with additional assistance during the Covid-19 pandemic in order to advance their treatment at home. It was introduced in Portugal, Finland, and Poland in 2021. The Gonal-f® pen's user-friendliness and patient-friendliness were highlighted in a number of studies involving patients seeking fertility treatment and nurses. The first product with recombinant follicle-stimulating hormone (r-hFSH) and recombinant luteinizing hormone (r-hLH) combined in a ready-to-use liquid form is Merck's Pergoveris® pen, which does not require mixing. As a result, it is an effective treatment for women who have severe FSH and LH deficiency. The Pergoveris® Pen was successfully introduced in India, Mexico, and Ecuador in Q3 2021 and is now offered in 44 nations. Launches will keep happening all over the world to give patients access to this treatment.
2. Continued investments to expand capabilities and production: Merck announced in March 2021 that it would expedite its plans for European expansion by establishing a single-use assembly production facility at its Molsheim, France, location. They are responding to the unprecedented global demand for this crucial technology, which is used to produce the Covid-19 vaccine and other life-saving treatments, with the € 25 million investment. Merck announced an investment in June 2021 to improve the company's development and production of monoclonal antibodies as well as other vital drugs and vaccines. Included in this are €50 million for enhancing bioproduction activities at their French facility in Martillac, resulting in the creation of 150 jobs through 2024. These expansion plans, along with their investment in Molsheim, France, are a part of an ambitious multi-year programme that aims to increase the industrial capabilities of its business sector in order to meet the rising global demand for life-saving medications and significantly improve public health around the world. They declared the opening of their second facility in Carlsbad, California, in October 2021, greatly enlarging their global Contract Development Manufacturing Organization (CDMO) footprint. Its current capacity to support large-scale commercial and industrial manufacturing for viral gene therapy in a market expected to grow to € 9 billion by 2026 will more than double with the construction of this new € 100 million, 13,000 square metre facility.
The remaining section under "Strength" is available only in the 'Complete Report' on purchase.
Weakness
This section is available only in the 'Complete Report' on purchase.
Opportunity
This section is available only in the 'Complete Report' on purchase.
Threat
This section is available only in the 'Complete Report' on purchase.
Key Business Segments / Diversification :
Recent Acquisition / Mergers / Alliance / Joint Ventures / Divestitures :
Open Table PreviewChord Therapeutics SA | Bio-tech | 2021 | Acquisition | The acquisition allows for the development of cladribine in generalised Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD) |
Exelead Inc., | Biopharmaceutical | 2021 | Acquisition | Exelead’s capacities and expertise will expand Merck’s service range for mRNA contract development and manufacturing, allowing it to provide a fully integrated offering across the entire mRNA manufacturing process. |
Complete Report
USD 15.53
- Debit/Credit card
- PayPal
TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
You may also be interested in other analyses of Merck KGaA:
-
Merck KGaA Porter's Five Forces Analysis -
Merck KGaA VRIO Analysis -
Merck KGaA Value Chain Analysis -
Merck KGaA Covid-19 Impact Analysis -
Merck KGaA BCG Analysis -
Merck KGaA Segmentation, Targeting and Positioning (STP) Analysis -
Merck KGaA Ansoff Matrix Analysis
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Check Out Analysis of Other Relevant Companies
References used in Merck KGaA SWOT & PESTLE Analysis Report
1. Merck KGaA Annual Report - https://www.merckgroup.com/en/annualreport/2021/_assets/downloads/entire-merck-ar21.pdf
2. EU slashes forecast for economic growth as war’s fallout deepens - https://www.aljazeera.com/economy/2022/5/16/eu-slashes-economic-growth-as-wars-fallout-spreads
3. Merck Invests Approximately € 100 Million to Accelerate Single-Use Manufacturing in China - https://www.sigmaaldrich.com/IN/en/collections/press/investment-to-accelerate-single-use-manufacturing-in-china
4. Press Releases - https://www.merckgroup.com/en/news.html
The detailed complete set of references are available on request in the 'Complete report' on purchase.
How to Reference This Page?
You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.
Merck KGaA SWOT and PESTLE Analysis - SWOT & PESTLE.COM
SWOT & PESTLE.com (2024). Merck KGaA SWOT and PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/merck/ [Accessed 05 Dec, 2024].
In-text: (SWOT & PESTLE.com, 2024)
Copyrights and Disclaimer
Merck KGaA SWOT and PESTLE analysis has been conducted by Sachin Mishra and reviewed by senior analysts from Barakaat Consulting.
Copyright of Merck KGaA SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.